Methods and devices for renal nerve blocking

Inactive Publication Date: 2008-09-04
ARDIAN
View PDF99 Cites 416 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0015]Surgical denervation of the kidney in experimental animals suggested multiple immediate and long-term benefits for patients with cardiac and renal diseases. The most significant potential beneficial effects are: slowing of the progression of CHF, resolution of fluid overload in CHF by induction or enhancement of diuresis, reduction of remodeling after a myocardial infarct, reduction of hypertension and slowing of the progression of chronic renal disease to dialysis. The benefits are achieved via the reduction of the systemic sympathetic tone causing vasoconstriction of blood vessels, reduction of the load on the heart and the dir

Problems solved by technology

It requires a major surgery and is ineffective in long term, since renal nerves eventually grow back.
Additionally, after the surgical denervation, the renal nerve can re-grow in a pathological way and can cause pain and other serious side effects.
Since fibrotic changes at the site of denervation make repeat surgical denervati

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods and devices for renal nerve blocking
  • Methods and devices for renal nerve blocking
  • Methods and devices for renal nerve blocking

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0036]For the proposed clinical use, the capability of the invention is to block the sympathetic activity of the renal nerve of the kidney by controlled local delivery of a nerve-blocking agent with the goal of improving the patient's renal and cardiac function. Elements of the invention are useful for blocking nerves for the purpose other than treating cardiorenal disease and can be applied in other anatomic locations.

[0037]A nerve blocking agent is a drug that reduces or blocks conduction of signals by renal nerves. The nerve blocking agents used can be selected from different groups including (1) local anesthetics, (2) ketamine (a well known sedative with nerve blocking properties), (3) tricyclic antidepressants such as amitriptyline, (4) neurotoxins such as tetrodotoxin and saxitoxin or (5) any other class or type of agent that transiently or permanently, partially or completely alters nerve conduction. The terms nerve blocking agent and nerve blocking drug are interchangeable.

[...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Lengthaaaaaaaaaa
Lengthaaaaaaaaaa
Pore sizeaaaaaaaaaa
Login to view more

Abstract

A method and apparatus for treatment of cardiac and renal diseases associated with the elevated sympathetic renal nerve activity by implanting a device to block the renal nerve signals to and from the kidney. The device can be a drug pump or a drug eluding implant for targeted delivery of a nerve-blocking agent to the periarterial space of the renal artery.

Description

RELATED APPLICATIONS[0001]This application is related and claims priority to the following commonly-owned applications, Ser. No. 60 / 408,665, entitled “Renal Nerve Stimulation Method And Apparatus For Treatment Of Patients” that was filed in the U.S. Patent and Trademark Office (USPTO) on Apr. 8, 2003 and provisional applications Ser. No. 60 / 370,190, entitled “Modulation Of Renal Nerve To Treat CHF”, that was filed in the U.S. Patent and Trademark Office (USPTO) on Apr. 8, 2002; Ser. No. 60 / 415,575 entitled “Modulation Of Renal Nerve To Treat CHF”, that was filed in the USPTO on Oct. 3, 2002, and Ser. No. 60 / 442,970 entitled “Treatment Of Renal Failure And Hypertension”, that was filed in the USPTO on Jan. 29, 2003. The entirety of each of these applications is incorporated by reference herein.FIELD OF THE INVENTION[0002]This invention relates to devices and methods for local drug delivery, and in particular is directed to an implantable system for targeted delivery of a nerve blocki...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61F2/00A61N1/02A61M5/00A61N1/32A61N1/36A61N1/362
CPCA61M5/14276A61M5/1723A61M2210/1082A61N1/0551A61N1/326A61N1/36007A61M2005/14513A61N1/36117A61N1/3627A61K9/0012A61K9/7007A61L29/146A61M5/145A61N1/36114A61M2205/05A61M2205/50A61K9/0004A61K31/135A61K31/52A61K31/529A61K45/06
Inventor GELFAND, MARKLEVIN, HOWARD R.
Owner ARDIAN
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap